Company Overview and News

 
Lion One Announces Drilling and Development Update for the Tuvatu Gold Project in Fiji

2017-05-09 accesswire
NORTH VANCOUVER, BC / ACCESSWIRE / May 9, 2017 / Lion One Metals Limited (TSXV: LIO) (ASX: LLO) (OTCQX: LOMLF) (FSE: LY1) (the "Company") is pleased to announce the following drilling and development update for its 100% owned and fully permitted high grade underground Tuvatu Gold Project located near Nadi on the island of Viti Levu in the Republic of Fiji.
Upvote Downvote

 
Lion One Will Be The Next Gold Mine In Fiji

2017-04-27 seekingalpha
Lion One is exploring for gold in the Fiji, and the main project is in the financing phase.
Upvote Downvote

 
NexOptic: Seeing Through The Blurred Hype; 88% Downside

2017-04-21 seekingalpha
NXO appears to be little more than a stock promotion, up 250% this year and valued at $300M all on the back of hype, not changes in fundamentals.
Upvote Downvote

 
Lion One Appoints John Robinson to Board of Directors

2017-04-12 accesswire
NORTH VANCOUVER, BC / ACCESSWIRE / April 11, 2017 / Lion One Metals Limited (TSX-V: LIO) (ASX: LLO) (OTCQX: LOMLF) (the "Company") is pleased to announce the appointment of Mr. John F. Robinson as an independent member of Lion One's Board of Directors and Audit Committee.
Upvote Downvote

 
Lion One Intersects 13.52 g/t Gold over 9.07 Meters at Tuvatu

2017-02-14 accesswire
NORTH VANCOUVER, BC / ACCESSWIRE / February 14, 2017 / Lion One Metals Limited (TSXV: LIO) (ASX: LLO) (OTCQX: LOMLF) (FSE: LY1) (the "Company") is pleased to announce further results from its ongoing drilling program at its 100% owned and fully permitted Tuvatu Gold Project located near Nadi on the island of Viti Levu in the Republic of Fiji.
Upvote Downvote

 
Lion One Intersects 24.54 g/t Gold Over 2.42 m; Drilling and Dewatering Update for Tuvatu Gold Project in Fiji

2016-12-21 marketwired
NORTH VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 21, 2016) - Lion One Metals Limited (TSX VENTURE:LIO)(ASX:LLO)(OTCQX:LOMLF)(FRANKFURT:LY1) (the "Company") is pleased to announce a drilling and dewatering update from its 100% owned and fully permitted Tuvatu Gold Project located near Nadi on the island of Viti Levu in the Republic of Fiji.
Upvote Downvote

 
Lion One Announces Annual General Meeting Results

2016-12-17 marketwired
NORTH VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 16, 2016) - Lion One Metals Limited (TSX VENTURE:LIO)(FRANKFURT:LY1)(OTCQX:LOMLF)(ASX:LLO) ("Lion One" or the "Company") announces the voting results from its Annual and Special General Meeting held on December 15, 2016 (the "Meeting"). A total of 69,280,427 common shares were represented at the Meeting, representing 68.11% of the Company's 101,722,044 common shares outstanding on the October 31, 2016 record date for the Meeting.
Upvote Downvote

 
Lion One Intersects 71.41 g/t Gold over 8.41 Meters at Tuvatu

2016-11-23 marketwired
NORTH VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 23, 2016) - Lion One Metals Limited (TSX VENTURE:LIO) (ASX:LLO) (OTCQX:LOMLF) (FRANKFURT:LY1) (the "Company") is pleased to announce that drilling, dewatering, and development has begun at the Company's 100% owned and fully permitted Tuvatu Gold Project located on the island of Viti Levu in Fiji.
Upvote Downvote

 
Lion One Announces Fiji Gold Exploration and Development Update

2016-10-12 marketwired
NORTH VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 12, 2016) - Lion One Metals Limited (TSX VENTURE:LIO)(ASX:LLO)(OTCQX:LOMLF)(FRANKFURT:LY1) (the "Company") is pleased to announce that it has submitted a tender for the acquisition of the Navilawa tenement directly adjoining the Company's 100% owned and fully permitted Tuvatu Gold Project, located on the island of Viti Levu in Fiji. The Company also announces that exploration on a new discovery is underway at the Jomaki Ridge Prospect inside the Tuvatu Mining Lease, and that dewatering and drilling contractors have been retained and mobilized for the next phase of development at Tuvatu.
Upvote Downvote

 
Lion One Announces Completion of $38 Million Private Placement

2016-09-16 marketwired
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA
Upvote Downvote

 
Lion One Announces Non-Brokered Private Placement

2016-08-29 marketwired
NORTH VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 29, 2016) - Lion One Metals Limited (TSX VENTURE:LIO )(ASX:LLO)(OTCQX:LOMLF)(FRANKFURT:LY1) (the "Company") is pleased to announce it has arranged, subject to the approval of the TSX Venture Exchange, a non-brokered private placement (the "Private Placement") of up to 45,000,000 units (the "Units") at a price of $0.92 per Unit for total gross proceeds of up to $41,400,000.
Upvote Downvote

 
Lion One Announces MOU for EPC Contract and Vendor Financing with Ansteel-CapitalAsia for Construction of the Tuvatu Gold Project

2016-08-24 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 24, 2016) - Lion One Metals Limited (TSX VENTURE:LIO)(ASX:LLO)(OTCQX:LOMLF)(FRANKFURT:LY1) (the "Company") is pleased to announce the signing of a non-binding Memorandum of Understanding (MOU) for an EPC Contract and Vendor Financing Agreement with Ansteel-CapitalAsia Global Engineering Inc. (the EPC Contractor, or Ansteel) covering a comprehensive Engineering, Procurement, Construction, and financing package for the development of the Company's 100% owned and fully permitted Tuvatu Gold Project in Fiji.
Upvote Downvote

 

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...